Skip to main content
. 2022 Feb 24;145(5):1598–1609. doi: 10.1093/brain/awac077

Figure 2.

Figure 2

Mass spectrometry-based proteomics biomarker development in frontotemporal dementia and amyotrophic lateral sclerosis. Patient plasma/serum and CSF samples are processed and analysed by liquid chromatography and mass spectrometry. Proteins identified as potential biomarkers for frontotemporal dementia and amyotrophic lateral sclerosis are listed with their references.